The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease

Experimental Neurology

Volumn 188, Issue 2, 2004, Pages 471-479

  Nash, J E ^a   Ravenscroft, P ^b   McGuire, S ^b   Crossman, A R ^b,c   Menniti, F S ^d   Brotchie, J M ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b Williams House   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d PFIZER INC   (United States)

Author keywords

Marmoset; MPTP; NMDA antagonist; NR2B subunit; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANTIPARKINSON AGENT; BENSERAZIDE PLUS LEVODOPA; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PROTEIN SUBUNIT; TRAXOPRODIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INJURY; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DYSKINESIA; FEMALE; MALE; MARMOSET; MONOTHERAPY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SYMPTOMATOLOGY;

ANIMALS; CALLITHRIX; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; FEMALE; LEVODOPA; MALE; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; PIPERIDINES; RANGE OF MOTION, ARTICULAR; RECEPTORS, N-METHYL-D-ASPARTATE; TREATMENT FAILURE;

EID: 3042833166     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.expneurol.2004.05.004     Document Type: Article

References (53)

1. Bezard E., Brotchie J.M., Gross C.E. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat. Rev., Neurosci. 2:2001;577
2. Blanchet P.J., Konitsiotis S., Chase T.N. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov. Disord. Off. J. Mov. Disord. Soc. 13:1998;798
3. Blanchet P.J., Konitsiotis S., Whittemore E.R., Zhou Z.L., Woodward R.M., Chase T.N. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl- tetrahydropyridine monkeys. J. Pharmacol. Exp. Ther. 290:1999;1034
4. Brimecombe J.C., Boeckman F.A., Aizenman E. Functional consequences of NR2 subunit composition in single recombinant N-methyl-D-aspartate receptors. Proc. Natl. Acad. Sci. U. S. A. 94:1997;11019
5. Brimecombe J.C., Gallagher M.J., Lynch D.R., Aizenman E. An NR2B point mutation affecting haloperidol and CP101, 606 sensitivity of single recombinant N-methyl-D-aspartate receptors. J. Pharmacol. Exp. Ther. 286:1998;627
6. Brotchie J.M. Novel approaches to the symptomatic treatment of parkinsonian syndromes: alternatives and adjuncts to dopamine-replacement. Curr. Opin. Neurol. 10:1997;340
7. Brotchie J.M. Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov. Disord. Off. J. Mov. Disord. Soc. 13:1998;871
8. Calon F., Morissette M., Ghribi O., Goulet M., Grondin R., Blanchet P.J., Bedard P.J., Di P.T. Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated monkeys following dopamine agonist treatment. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 26:2002;127
9. Carroll C.B., Holloway V., Brotchie J.M., Mitchell I.J. Neurochemical and behavioural investigations of the NMDA receptor-associated glycine site in the rat striatum: functional implications for treatment of parkinsonian symptoms. Psychopharmacology (Berlin). 119:1995;55
10. Chase T.N., Oh J.D. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann. Neurol. 47:2000;S122
11. Chase T.N., Oh J.D., Konitsiotis S. Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. J. Neurol. 247(Suppl. 2):2000;II36
12. Chase T.N., Konitsiotis S., Oh J.D. Striatal molecular mechanisms and motor dysfunction in Parkinson's disease. Adv. Neurol. 86:2001;355
13. Chazot P.L., Lawrence S., Thompson C.L. Studies on the subtype selectivity of CP-101, 606: evidence for two classes of NR2B-selective NMDA receptor antagonists. Neuropharmacology. 42:2002;319
14. Dunah A.W., Standaert D.G. Subcellular segregation of distinct heteromeric NMDA glutamate receptors in the striatum. J. Neurochem. 85:2003;935
15. Engber T.M., Papa S.M., Boldry R.C., Chase T.N. NMDA receptor blockade reverses motor response alterations induced by levodopa. NeuroReport. 5:1994;2586
16. Fox S.H., Henry B., Hill M., Crossman A., Brotchie J. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov. Disord. Off. J. Mov. Disord. Soc. 17:2002;1180
17. Gallagher M.J., Huang H., Pritchett D.B., Lynch D.R. Interactions between ifenprodil and the NR2B subunit of the N-methyl-D-aspartate receptor. J. Biol. Chem. 271:1996;9603
18. Greenamyre J.T. Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease. J. Neural Transm.: Gen. Sect. 91:1993;255
19. Henry B., Fox S.H., Crossman A.R., Brotchie J.M. Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Exp. Neurol. 171:2001;139
20. Henry B., Fox S.H., Peggs D., Crossman A.R., Brotchie J.M. The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Mov. Disord. Off. J. Mov. Disord. Soc. 14:1999;744
21. Hille C.J., Fox S.H., Maneuf Y.P., Crossman A.R., Brotchie J.M. Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's disease. Exp. Neurol. 172:2001;189
22. Jenner P. The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease. Parkinsonism Relat. Disord. 9:2003;131
23. Jenner P., Rupniak N.M., Rose S., Kelly E., Kilpatrick G., Lees A., Marsden C.D. 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced parkinsonism in the common marmoset. Neurosci. Lett. 50:1984;85
24. Kemp J.A., Mckernan R.M. NMDA receptor pathways as drug targets. Nat. Neurosci. 5:2002;1039
25. Konieczny J., Ossowska K., Schulze G., Coper H., Wolfarth S. L-701, 324, a selective antagonist at the glycine site of the NMDA receptor, counteracts haloperidol-induced muscle rigidity in rats. Psychopharmacology (Berlin). 143:1999;235
26. Laube B., Kuhse J., Betz H. Evidence for a tetrameric structure of recombinant NMDA receptors. J. Neurosci. Off. J. Soc. Neurosci. 18:1998;2954
27. Laurie D.J., Seeburg P.H. Ligand affinities at recombinant N-methyl-D-aspartate receptors depend on subunit composition. Eur. J. Pharmacol. 268:1994;335
28. Loschmann P.A., De Groote C., Smith L., Wullner U., Fischer G., Kemp J.A., Jenner P., Klockgether T. Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease. Exp. Neurol. 187:2004;86-93
29. Luginger E., Wenning G.K., Bosch S., Poewe W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov. Disord. Off. J. Mov. Disord. Soc. 15:2000;873
30. Marino M., Valenti O., Conn P.J. Glutamate receptors and Parkinson's disease: opportunities for intervention. Drugs Aging. 20:2003;377
31. Mitchell I.J., Cross A.J., Sambrook M.A., Crossman A.R. Neural mechanisms mediating 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced parkinsonism in the monkey: relative contributions of the striatopallidal and striatonigral pathways as suggested by 2-deoxyglucose uptake. Neurosci. Lett. 63:1986;61
32. Monyer H., Giffard R.G., Hartley D.M., Dugan L.L., Goldberg M.P., Choi D.W. Oxygen or glucose deprivation-induced neuronal injury in cortical cell cultures is reduced by tetanus toxin. Neuron. 8:1992;967
33. Mott D.D., Doherty J.J., Zhang S., Washburn M.S., Fendley M.J., Lyuboslavsky P., Traynelis S.F., Dingledine R. Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition. Nat. Neurosci. 1:1998;659
34. 3H]Ro 25-6981, a potent and selective antagonist of NMDA receptors containing NR2B subunits. J. Neurochem. 70:1998;2147
35. Nash J.E., Brotchie J.M. Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat. Mov. Disord. Off. J. Mov. Disord. Soc. 17:2002;455
36. Nash J.E., Hill M.P., Brotchie J.M. Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat. Exp. Neurol. 155:1999;42
37. Nash J.E., Fox S.H., Henry B., Hill M.P., Peggs D., McGuire S., Maneuf Y., Hille C., Brotchie J.M., Crossman A.R. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Exp. Neurol. 165:2000;136
38. Oh J.D., Chase T.N. Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease. Amino Acids. 23:2002;133
39. Oh J.D., Russell D.S., Vaughan C.L., Chase T.N., Russell D. Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration. Brain Res. 813:1998;150
40. Oh J.D., Vaughan C.L., Chase T.N. Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits. Brain Res. 821:1999;433
41. Ossowska K., Lorenc-Koci E., Konieczny J., Wolfarth S. The role of striatal glutamate receptors in models of Parkinson's disease. Amino Acids. 14:1998;11
42. Papa S.M., Chase T.N. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann. Neurol. 39:1996;574
43. Papa S.M., Boldry R.C., Engber T.M., Kask A.M., Chase T.N. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res. 701:1995;13
44. Pearce R.K., Jackson M., Smith L., Jenner P., Marsden C.D. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated common marmoset (Callithrix jacchus). Mov. Disord. Off. J. Mov. Disord. Soc. 10:1995;731
45. Penney J.B., Young A.B. Striatal inhomogeneities and basal ganglia function. Mov. Disord. Off. J. Mov. Disord. Soc. 1:1986;3
46. Perin-Dureau F., Rachline J., Neyton J., Paoletti P. Mapping the binding site of the neuroprotectant ifenprodil on NMDA receptors. J. Neurosci. Off. J. Soc. Neurosci. 22:2002;5955
47. Rascol O. Medical treatment of levodopa-induced dyskinesias. Ann. Neurol. 47:2000;S179
48. Robertson R.G., Graham W.C., Sambrook M.A., Crossman A.R. Further investigations into the pathophysiology of MPTP-induced parkinsonism in the primate: an intracerebral microdialysis study of gamma-aminobutyric acid in the lateral segment of the globus pallidus. Brain Res. 563:1991;278
49. Steece-Collier K., Chambers L.K., Jaw-Tsai S.S., Menniti F.S., Greenamyre J.T. Antiparkinsonian actions of CP-101, 606, an antagonist of NR2B subunit-containing N-methyl-D-aspartate receptors. Exp. Neurol. 163:2000;239
50. Ulas J., Weihmuller F.B., Brunner L.C., Joyce J.N., Marshall J.F., Cotman C.W. Selective increase of NMDA-sensitive glutamate binding in the striatum of Parkinson's disease, Alzheimer's disease, and mixed Parkinson's disease/Alzheimer's disease patients: an autoradiographic study. J. Neurosci. Off. J. Soc. Neurosci. 14:1994;6317
51. Verhagen-Metman L., Del-Dotto P., Natte R., van-den-Munckhof P., Chase T.N. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology. 51:1998;203
52. Verhagen-Metman L., Del-Dotto P., van-den-Munckhof P., Fang J., Mouradian M.M., Chase T.N. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology. 50:1998;1323
53. Weihmuller F.B., Ulas J., Nguyen L., Cotman C.W., Marshall J.F. Elevated NMDA receptors in parkinsonian striatum. NeuroReport. 3:1992;977